Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Milano 20133

0 studies enrolling now · 4 studies all time

What they study most

Advanced Malignancies, Conventional Chondrosarcoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, NSCLC, Ovarian Cancer, Progressive Brain Metastasis, Solid Tumors, Unresectable or Metastatic Melanoma, Urothelial Cancer

Studies at this site

• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma — Stopped early
• Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing — Running, not enrolling
• Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma — Running, not enrolling
• A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma — Completed